|
Isakova et al., CJASN [20]
|
Placebo; LC; P-restricted diet + placebo; P-restricted diet + LC
|
cFGF23 only
|
39
|
3–4
|
12 weeks
|
Significant 35% reduction in FGF23 in the P-restricted + LC group at week 12 vs baseline.
|
|
No significant change in FGF23 from baseline in other groups.
|
|
Yilmaz et al., AJKD [32]
|
Sevelamer; Calcium acetate
|
iFGF23
|
100
|
4
|
8 weeks
|
Sevelamer group: reduction (27.1%) at week 8.
|
|
Calcium acetate group: increase (3.5%) at week 8. Significance of changes from baseline not specified.
|
|
Oliveira et al., CJASN [18]
|
Calcium acetate; Sevelamer hydrochloride
|
iFGF23
|
40
|
3–4
|
6 weeks
|
For patients with stage 3 CKD:
|
|
• Sevelamer group: significant reduction in FGF23 at week 6 (34.6%).
|
|
• Calcium group: non-significant reduction in FGF23 at week 6 (24.7%).
|
|
Isakova et al., NDT [24]
|
LC; Placebo (both on P-controlled diet either 750 mg or 1500 mg)
|
cFGF23
|
16
|
3–4
|
2 weeks
|
No significant change from baseline.
|
|
Slight increase from baseline in the group ingesting 1500 mg P + placebo.
|
|
Block et al., JASN [31]
|
Placebo; Calcium acetate; Sevelamer; LC
|
cFGF23 and iFGF23
|
148
|
3–4
|
9 months
|
No significant differences in cFGF23.
|
|
Change from baseline of iFGF23:
|
|
• Sevelamer: small but significant reduction.
|
|
• Calcium acetate: small but significant increase.
|
|
• LC and Placebo: no change.
|
|
Gonzalez-Parra et al., NDT [19]
|
LC
|
cFGF23
|
18
|
3
|
4 weeks
|
Significant reduction (21.8%) from baseline of cFGF23.
|
